Table 3.
Outcome of objectives of all included studies.
| Study (Year) | Number and Type of Cases | Age | Follow-Up Time | Primary VSCC Risk in dVIN | Recurrent VSCC Risk in dVIN/VSCC | ||||
|---|---|---|---|---|---|---|---|---|---|
| Risk of Primary VSCC | Time to Progression | Risk of Recurrent VSCC | Time to Progression | ||||||
| Years, Median (Range) | Months, Median (Range) | Number of Primary VSCC | Absolute Risk (%) | Months, Median (Range) | Number of Recurrent VSCC | Absolute Risk (%) | Months, Median (Range) | ||
| Yang et al. (2000) [22] | 8 dVIN 1 | 67.5 (55–82) | 48.5 (14–121) | 3 | 37.5 | 9 (6–55) | - | - | - |
| Van de Nieuwenhof et al. (2009) [18] | 67 dVIN | 67 | NA | 22 | 32.8 | 22.8 (3–84) | - | - | - |
| Regauer et al. (2016) [19] | 16 dVIN | NA | NA | 9 | 56.3 | NA | - | - | - |
| Thuijs et al. (2020) [7] | 12 dVIN | 70.3 (40.3–85.3) | 167 (4–329) 2 | 7 | 58.3 | 16.8 | - | - | - |
| McAlpine et al. (2017) [20] | 7 dVIN 18 dVIN/VSCC |
75.1 3 75.8 3 |
72 NA |
6 - |
85.7 - |
22.8 - |
- 17 |
- 94.4 |
- 13.2 |
| Eva et al. (2008) [21] | 44 dVIN/VSCC | NA | NA | - | - | - | 14 | 31.8 | NA |
| Te Grootenhuis et al. (2019) [17] | 197 dVIN/VSCC | 73 (26–100) 4 | 80 (0–204) | - | - | - | 94 5 | 47.7 | 32 (0–202) 6 |
1 Referred to as simplex VIN in the article; 2 Follow-up time for entire study population (n = 894); 3 Mean age; 4 Median age for entire study population (n = 287); 5 Number of cases calculated from reported 10-year recurrent risk in dVIN/VSCC cohort; 6 Time to progression for entire study population (n = 287), did not differ significantly between adjacent precursor lesion groups (p = 0.08). Abbreviations: dVIN, differentiated vulvar intraepithelial neoplasia (cases without history of vulvar cancer); dVIN/VSCC, dVIN adjacent to vulvar squamous cell carcinoma; NA, not available; VSCC, vulvar squamous cell carcinoma.